FindTrial
Sign In

Ertugliflozin 15 mg

DRUG7 trials

Sponsors

Merck Sharp & Dohme LLC, Amsterdam UMC, location VUmc

Conditions

Diabetes MellitusDiabetic Kidney DiseaseDiabetic NephropathyErtugliflozinHepatic ImpairmentHypertensionRenal HypoxiaRenoprotection

Phase 1

Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)
CompletedNCT02115347
Merck Sharp & Dohme LLCHepatic Impairment, Type 2 Diabetes Mellitus
Start: 2014-09-19End: 2015-01-19Updated: 2018-08-20

Phase 3

A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).
CompletedNCT02033889
Merck Sharp & Dohme LLCType 2 Diabetes Mellitus
Start: 2013-12-13End: 2017-08-03Updated: 2018-09-10
Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)
CompletedNCT02036515
Merck Sharp & Dohme LLCType 2 Diabetes Mellitus
Start: 2014-03-12End: 2016-06-06Updated: 2018-09-13
A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)
CompletedNCT02630706
Merck Sharp & Dohme LLCType 2 Diabetes Mellitus
Start: 2015-12-16End: 2017-12-27Updated: 2018-12-07
Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)
CompletedNCT04029480
Merck Sharp & Dohme LLCType 2 Diabetes Mellitus
Start: 2019-10-08End: 2025-04-11Updated: 2025-10-31

Phase 4

Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.
CompletedNCT04027530
Amsterdam UMC, location VUmcDiabetic Kidney Disease, Diabetic Nephropathy, Ertugliflozin +4
Start: 2020-12-10End: 2023-01-09Updated: 2023-05-01
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study
CompletedNCT05727579
Amsterdam UMC, location VUmcDiabetes Mellitus, Diabetic Kidney Disease, Hypertension
Start: 2023-07-03End: 2025-11-30Updated: 2026-04-15

Related Papers

Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity
Diabetes Therapy2023-02-012 citations
The effects of ertugliflozin on β‐cell function: Pooled analysis from four phase 3 randomized controlled studies
Diabetes Obesity and Metabolism2020-07-236 citations
Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
Diabetes Therapy2020-07-0914 citations
Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials.
2020-05-0518 citations
Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus
Current Medical Research and Opinion2020-04-2310 citations
Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus
Current Medical Research and Opinion2020-04-233 citations
Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials
Diabetologia2020-03-3140 citations
Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus.
2020-01-039 citations
Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies
Diabetes and Vascular Disease Research2019-05-1325 citations
Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials
Cardiovascular Diabetology2019-05-0720 citations
Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia
Diabetes Obesity and Metabolism2019-03-0449 citations
Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET trial
Diabetes Obesity and Metabolism2019-01-0863 citations
Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment.
2018-09-1416 citations
A Pooled Analysis of the Efficacy and Safety of Ertugliflozin as Add-On Therapy to Metformin
Diabetes2018-06-223 citations
Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.
2018-02-2363 citations
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
2017-10-23115 citations
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
2017-10-02137 citations